[{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CYB004","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Lyndra Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Inversago Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"INV-202","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"ImmuneOnco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IMM0306","moa":"CD20\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Coagulation Factor X","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Artelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cassava Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MELT-100","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MELT-300","moa":"GABAA receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"15","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH||Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SP-103","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HT-001","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Gate Neurosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Syndeio Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"9","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Neurotrope"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cereno Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Corteria Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"COR-1167","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PH100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NDI-219216","moa":"WRN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"}]
Find Clinical Drug Pipeline Developments & Deals by Worldwide Clinical Trials
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
